InterCure (INCR.TA) Osake Kurssi
InterCure Kurssi
Viimeisten 19 vuoden aikana InterCuren liikevaihto kasvoi 14,3 % vuodessa ja ylsi 238,85 M ILS:een. Osakekohtainen tulos on laskenut 24,6 % vuodessa viimeisten 10 vuoden aikana. InterCuren nettomarginaali −28,4 % on noussut verrattuna −57,2 %:iin muutama vuosi sitten. InterCuren 12 kuukauden konsensustavoitehinta on 7,14 ILS, noin ali kurssia 55,2 %. 7 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
InterCure osakekurssi
InterCure liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset InterCure -osakkeesta
InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.
InterCure Ltd is primarily active in the medical cannabis industry.
The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.
InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.
InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.
InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.
InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.
Analyytikot asettavat tällä hetkellä InterCure-osakkeelle keskimääräisen tavoitehinnan 7,14 ILS (mediaani: 7,14 ILS), mikä merkitsee −55,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 7 analyytikkoarvioon.
7 analyytikkoa arvioi tällä hetkellä InterCure-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat InterCure-yhtiöltä 574,00 M ILS liikevaihtoa ja 1,70 ILS osakekohtaista tulosta.
Nykyisellä valuuttakurssilla InterCure-osake noteerataan hintaan 4,63 EUR (15,92 ILS).
InterCure-osake (INCR.TA) on listattuna 2 pörssissä, muun muassa: NASDAQ (INCR).
InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.
odotettu liikevaihto InterCure on 574,00 M ILS. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto InterCure on 78,13 M ILS. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
InterCure:n hinta-voitto-suhde (P/E) on tällä hetkellä 9,35. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan InterCure-osakkeen arvostusta.
InterCure:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,27. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii InterCure-osakkeen arvostuskennuslukuna.
InterCure:n Eulpool-laatuscore on 1/10.
InterCure:n ISIN on IL0011063760. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
InterCure:n WKN on A1CZA8. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
InterCure:n ticker on INCR.TA. Tämä pörssinoteeraus käytetään InterCure-osakkeiden kauppaan pörssissä.
InterCure osake
InterCure vertaisryhmä
InterCure Ticker
InterCure FIGI
Kaikki tunnusluvut ja syvällinen analyysi InterCure:sta
Meidän osakeanalyysimme InterCure-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut InterCure:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: